We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$40.7B
AUM Growth
-$4.56M
(-0.01%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
19.9%
Holding
801
New
88
Increased
169
Reduced
396
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$165M |
| 2 |
Costco
COST
|
+$134M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$126M |
| 4 |
Johnson Controls International
JCI
|
+$121M |
| 5 |
3M
MMM
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$136M |
| 3 |
Marathon Petroleum
MPC
|
+$123M |
| 4 |
CenterPoint Energy
CNP
|
+$123M |
| 5 |
Under Armour
UAA
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.42% |
| 2 | Healthcare | 16.85% |
| 3 | Financials | 12.9% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Industrials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Genpact
G
$5.96B
| $29.5M | 0.07% |
700,000
+200,000
| +40% | +$7.99M |
|
302
Allstate
ALL
$68B
| $29.5M | 0.07% |
262,213
-87,900
| -25% | -$9.59M |
|
|
SIVB
303
DELISTED
SVB Financial Group
SIVB
| $29.3M | 0.07% |
116,900
-4,900
| -4% | -$1.11M |
|
304
Eli Lilly
LLY
$1.02T
| $29.1M | 0.07% |
221,561
-196,700
| -47% | -$22.8M |
|
305
Monster Beverage
MNST
$94.3B
| $28.8M | 0.07% |
906,522
-42,200
| -4% | -$1.24M |
|
|
XENT
306
DELISTED
Intersect ENT, Inc
XENT
| $28.6M | 0.07% |
1,150,000
+250,000
| +28% | +$5.07M |
|
307
Freeport-McMoran
FCX
$90B
| $28.6M | 0.07% |
2,182,300
-360,300
| -14% | -$3.96M |
|
308
Crown Holdings
CCK
$12.8B
| $28.4M | 0.07% |
391,631
-780,300
| -67% | -$55.6M |
|
309
Boston Properties
BXP
$11.2B
| $28.3M | 0.07% |
205,318
-68,346
| -25% | -$9.21M |
|
310
Astec Industries
ASTE
$1.16B
| $28.2M | 0.07% |
671,642
-100,000
| -13% | -$3.63M |
|
311
Aptiv
APTV
$12B
| $28.2M | 0.07% |
+296,700
| New | +$27.2M |
|
312
Realty Income
O
$59.6B
| $27.9M | 0.07% |
391,747
-1,548
| -0.4% | -$115K |
|
313
RingCentral
RNG
$4.66B
| $27.8M | 0.07% |
+165,000
| New | +$27.2M |
|
314
SBA Communications
SBAC
$19.2B
| $27.5M | 0.07% |
114,200
+88,800
| +350% | +$21.1M |
|
315
DTE Energy
DTE
$29.5B
| $27.5M | 0.07% |
+248,395
| New | +$26.8M |
|
|
PRNB
316
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $27.4M | 0.07% |
500,000
+100,000
| +25% | +$3.73M |
|
317
Las Vegas Sands
LVS
$31.7B
| $27.1M | 0.07% |
+391,900
| New | +$24.5M |
|
|
CERN
318
DELISTED
Cerner Corp
CERN
| $26.8M | 0.07% |
365,520
-20,900
| -5% | -$1.45M |
|
319
AXIS Capital
AXS
$7.68B
| $26.4M | 0.06% |
444,137
+354,137
| +393% | +$21.4M |
|
320
Royal Caribbean
RCL
$85.1B
| $26.4M | 0.06% |
197,500
-9,500
| -5% | -$1.11M |
|
|
FITB
321
Fifth Third Bancorp
FITB
$51.2B
| $26.3M | 0.06% |
856,600
-739,300
| -46% | -$21.7M |
|
322
Amphenol
APH
$198B
| $26.3M | 0.06% |
972,852
-165,600
| -15% | -$4.23M |
|
323
Paychex
PAYX
$41.6B
| $26.3M | 0.06% |
308,746
+51,400
| +20% | +$4.34M |
|
324
uniQure
QURE
$3.03B
| $26.2M | 0.06% |
365,000
-35,000
| -9% | -$1.92M |
|
|
PARA
325
DELISTED
Paramount Global Class B
PARA
| $26.1M | 0.06% |
622,440
+224,705
| +56% | +$8.7M |
|
Similar funds
Adage Capital Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Adage Capital Partners held 801 positions worth $40.7B, down 0.01% from $40.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Adage Capital Partners withdrew a net $3.46B in Q4 2019, closing 90 positions and reducing 396 holdings. Its most notable exit was Celgene Corp, an estimated $1.48B position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $142M.
- Adage Capital Partners's largest Q4 2019 buy was Bristol-Myers Squibb: 2,207,539 shares worth $142M.
- Adage Capital Partners added most to RTX Corp in Q4 2019, an estimated $165M increase.
- Adage Capital Partners's biggest Q4 2019 reduction was Apple, cutting an estimated $136M.
- Adage Capital Partners fully exited Celgene Corp in Q4 2019, selling an estimated $1.48B.
- Adage Capital Partners's ten largest holdings make up 20% of its $40.7B portfolio in Q4 2019.
- Adage Capital Partners opened 88 new positions and closed 90 in Q4 2019.
- Adage Capital Partners's portfolio value fell 0.01% quarter-over-quarter to $40.7B.
Based on Adage Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.